| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REPORT |
Clinical Development, Medimmune, Inc, 35 W Watkins Mill Road, Gaithersburg, MD 20878, USA
Correspondence to:
Correspondence to:
Dr R L Wilder;
wilderr{at}medimmune.com
ABSTRACT
A substantial and persuasive body of data now exists that supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, migration, and bone resorption, and inflammatory angiogenesis. All of these processes play an important part in the pathogenesis of rheumatoid arthritis (RA) and related arthropathies. Animal arthritis model data further support these concepts and also suggest that therapeutic antagonism of integrin alpha V beta 3 is worthy of further investigation in RA and related arthropathies. To this end, Vitaxin, also known as MEDI-522, has been developed. Vitaxin is a humanised monoclonal IgG1 antibody that specifically binds a conformational epitope formed by both the integrin alpha V and beta 3 subunits. It blocks the interaction of alpha V beta 3 with various ligands such as osteopontin and vitronectin. Clinical trials with Vitaxin in patients with RA are in progress.
Keywords: osteoclasts; angiogenesis; integrins; rheumatoid arthritis; integrin alpha V beta 3
Abbreviations: RA, rheumatoid arthritis; ECM, extracellular matrix
This article has been cited by other articles:
|
|
 |
|
  R. J. Santulli, W. A. Kinney, S. Ghosh, B. L. DeCorte, L. Liu, R. W. A. Tuman, Z. Zhou, N. Huebert, S. E. Bursell, A. C. Clermont, et al. Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 894 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Danese, M. Sans, D. M Spencer, I. Beck, F. Donate, M. L Plunkett, C. de la Motte, R. Redline, D. E Shaw, A. D Levine, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis Gut, June 1, 2007; 56(6): 855 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mullamitha, N. C. Ton, G. J.M. Parker, A. Jackson, P. J. Julyan, C. Roberts, G. A. Buonaccorsi, Y. Watson, K. Davies, S. Cheung, et al. Phase I Evaluation of a Fully Human Anti-{alpha}v Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2128 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Dall'Acqua, P. A. Kiener, and H. Wu Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn) J. Biol. Chem., August 18, 2006; 281(33): 23514 - 23524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Liden, A. Berg, T. Nedrebo, R. K. Reed, and K. Rubin Platelet-Derived Growth Factor BB-Mediated Normalization of Dermal Interstitial Fluid Pressure After Mast Cell Degranulation Depends on {beta}3 but Not {beta}1 Integrins Circ. Res., March 17, 2006; 98(5): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smith, R. E. Kontermann, J. Embleton, and S. Kumar Antibody phage display technologies with special reference to angiogenesis FASEB J, March 1, 2005; 19(3): 331 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Neidhart, F Zaucke, R von Knoch, A Jungel, B A Michel, R E Gay, and S Gay Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein Ann Rheum Dis, March 1, 2005; 64(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cui, R. Subramanian, M. Shou, X. Yu, M. A. Wallace, M. P. Braun, B. H. Arison, J. A. Yergey, and T. Prueksaritanont IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN {alpha}v{beta}3 ANTAGONIST IN RATS, DOGS, AND MONKEYS Drug Metab. Dispos., August 1, 2004; 32(8): 848 - 861. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
